BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Turning Frontline Reality Into Policy Action For Cancer Care In Asia

Drawing on her frontline clinical experience in Malaysia, Prof Dr Wan Zamaniah, Consultant Clinical Oncologist, University Malaya Medical Centre&...

February 02, 2026 | Expert Insight

China Originated Innovation Is Rising. Global Expectations Are Rising Even Faster.

The momentum is real—and so is the level of scrutiny. As more programs move beyond regional boundaries, expectations from global biopharma companies ...

February 02, 2026 | News | By Anil Kane, executive director, global head of technical and scientific affairs, Thermo Fisher Scientific

From Capacity to Capability: How 2026 can be the catalyst for what APAC’s Biopharma Growth Needs Next

Beyond Scale: What Will Sustain APAC’s Biopharma Leadership Asia-Pacific’s rise in global biopharma is no longer about whether the region can ...

January 21, 2026 | News | By Joonho Choi, Vice President, Asia-Pacific, Cytiva

Navigating European Regulatory and Market Access Pathways: Crucial Considerations from TMC’s Catherine Moncad

As more APAC biotech and pharma companies look to Europe for regulatory approval and commercialisation, navigating complex EU and UK requirements early is ...

January 19, 2026 | News

Leading the Future of Care: Patient Organizations Driving Health System Transformation

Real Change Starts with Listening Across the Asia Pacific, Middle East, and Africa, healthcare systems are facing mounting pressures with rising rates of ...

January 05, 2026 | Opinion | By Sung Lee, Executive Director, Region Communications and Patient Advocacy, Asia Pacific, Middle East, Africa (APMA), Novartis

How Asia Pacific Is Forcing A Rethink On Surgical Outcomes Measurement

As surgical volumes rise and care pathways grow more complex across Asia Pacific, the limitations of how post operative outcomes are measured are becoming ...

January 05, 2026 | Expert Insight | By editor@biopharmaapac.com

2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know

At the centre of this momentum stood the U.S. Food and Drug Administration, whose 2025 approvals illustrated how medicine is moving decisiv...

December 29, 2025 | Analysis | By arcilla.fran@biopharmaapac.com

BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025

The year 2025 has marked a pivotal moment for the biopharmaceutical industry as it reckons with the aftershocks of a global pandemic and ongoing geopolitic...

December 24, 2025 | Analysis

How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026

Health systems have become more consolidated. Some are acting as both providers and payers, and therefore have more influence as gatekeepers of market acce...

December 10, 2025 | Report

Bringing Multi-Modal Intelligence to Early Clinical Recruitment

A protocol might specify a cohort defined by inflammatory markers, disease severity, a diagnostic pattern or a particular biological signature — but ...

December 10, 2025 | News | By Tom Stubbs, PHD – CEO of Hurdle.bio

Building Trust Through Quality: How QMS Powers Manufacturing Excellence in Life Sciences

Life sciences sector, a robust Quality Management System (QMS) has become the cornerstone of manufacturing excellence. This is especially true for the medi...

October 16, 2025 | Analysis

Building Biopharma Resilience: Cytiva’s Joonho Choi on the Power of Connected Ecosystems

Amid global supply chain disruptions, tightening regulations, and shifting patient needs, biopharma resilience has become both a stra...

October 15, 2025 | Interview

Anthony Elgamal: Redefining First-Line Treatment in EGFR-Mutated Lung Cancer

BioPharma APAC speaks with Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific, on th...

October 13, 2025 | Expert Insight

Turning Signals into Cures: The Big Data Blueprint for Cell Therapy Factories

Cell therapy manufacturing is entering a data-driven era, as the industry grapples with complex production processes, high costs, and the need for personal...

October 07, 2025 | Analysis

Stay Connected